Medicinal Genomics Corp. (MGC) of Beverly, Massachusetts, recently announced that AOAC International has approved its new technology for THC extraction.
MGC was certified for its standards in product consistency and stability, robustness, matrix studies and ability to accurately detect hazardous cannabis strains, according to a press release.
"We're very pleased with the AOAC's decision to certify our Aspergillus assays," Dr. Sherman Hom, Medical Genomics Director of Regulatory Affairs, said in a statement. "We've long been staunch proponents of molecular methods for pathogen testing across the cannabis matrix, and this AOAC validation signifies the value and importance of these methods to not only every state, but also every regulatory body across this rapidly developing industry."
MGC's PathoSEEK Microbial Safety Testing platform uses a two-step protocol to detect four hazardous species in both cannabis flower and cannabis infused edibles.
MGC is the first manufacturer to receive certification for cannabis-infused edibles; produces CannMed, an annual conference dedicated to the scientific advancement of the cannabis industry; and maintains Kannapedia, the world's most complete public cannabis cultivar database.
AOAC International is a global organization that provides standards for various analytical test methods and its accreditations are recognized by the U.S. Department of Agriculture and the U.S. Food and Drug Administration.